Revolution Medicines Inc RVMD

$206.64 +0.75 (0.36%)

Valuation

Market cap
44,129,636,000
Revenue TTM
$0
Net income TTM
$-1,131,300,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.40

Trading

Volume
1,570,400
Avg volume
1,906,734
Day's range
$204.07 – $208.82
Shares out
214,336,000
Stochastic %K
78%
Beta
1.40
Analysts
Strong Sell
Price target
$253.13

Price

Company profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to s...

Show more

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 481 6801
Website
https://www.revmed.com
Address
700 Saginaw Drive, Redwood City, United States

Latest news

Stocktwits

Florestan Oct 3, 6:08 AM
$RVMD RM-055 is coming.
0 replies
RonIsWrong Oct 3, 3:36 AM
$RVMD Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib. Gift article https://www.nytimes.com/2026/09/30/science/pancreatic-cancer-drug-daraxonrasib-ben-sasse-resistance.html?unlocked_article_code=1.F1E.XQ7A.B_bh22mz0eoo&smid=nytcore-android-share
0 replies
SellasgpsCurativeBAT11 Oct 2, 8:41 PM
$SLS mOS of the GPS ARM won’t be reached at 80Th event because over 65% of the GPS ARM will be still alive, while 0-1% of BAT ARM will be alive. mOS for GPS ARM won’t be reached for many years as the Remaining GPS ARM patients are functionally cured. GPS Regal Phase 3 Study will be declared a Paradigm Shifting Breakthrough success and MC will surpass $RVMD if Sellas is not bought out before that. All roads lead to BO as the ultimate and Final Outcome here. ✌️🙏❤️‍🩹
0 replies
Universaal Oct 2, 5:56 PM
$KOD this trash is $90 ??? Wow 😳 so does $RVMD
1 replies
Alt_Fuel Oct 2, 12:10 PM
$VSTM $VSTM / $RVMD ... " Verastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026 " October 2, 2026 at 7:32 AM EDT (Benzinga Newswire) RAMP 201 molecular profiling showed clinically meaningful activity in KRAS wild-type recurrent LGSOC, including ORRs of 22% in patients with NRAS- or BRAF-mutated tumors and 18% in patients with KRAS/NRAS/BRAF triple wild-type tumors External control analysis showed higher weighted ORR and statistically significant improvements in PFS versus conventional care in both KRAS-mutated and KRAS wild-type subgroups
0 replies
VicAge Oct 1, 7:38 PM
trampoline / floor building day. Get it nice and solid, and then bounce up to the next level. Everyone is getting nervous on the side lines wondering if they don't get in they are going to miss the big run up. Trying to time the local dip. It is no longer a failing knife but a rising rocket . . . Revolution $RVMD is $ 70 billion market cap with no revenue . . . the big players wanted to buy it out but the share prices kept on going up.
0 replies
Ne54467 Oct 1, 6:11 PM
$RVMD inching back up steady everyday into earnings.
0 replies
Waxapple88 Oct 1, 3:25 PM
$RVMD earnings report is estimated to be released on November 4, 2026
0 replies